Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 5Genitourinary 1

Conditions

Carcinoma, Transitional Cell 37Urinary Bladder Neoplasms 33Carcinoma, Renal Cell 30Carcinoma, Non-Small-Cell Lung 16Melanoma 15Prostatic Neoplasms 13Stomach Neoplasms 10Carcinoma, Hepatocellular 10Triple Negative Breast Neoplasms 9Kidney Neoplasms 9Colorectal Neoplasms 9Head and Neck Neoplasms 8Uterine Cervical Neoplasms 7Squamous Cell Carcinoma of Head and Neck 7Small Cell Lung Carcinoma 7Neoplasms 7Neoplasm Metastasis 6Lung Neoplasms 6Breast Neoplasms 6Ovarian Neoplasms 5Carcinoma, Merkel Cell 5Urologic Neoplasms 4Pancreatic Neoplasms 4Urethral Neoplasms 3Ureteral Neoplasms 3Esophageal Neoplasms 3Carcinoma, Squamous Cell 3Sarcoma 2Prostatic Neoplasms, Castration-Resistant 2Neuroendocrine Tumors 2

Interventions

pembrolizumab 3Trastuzumab 2Nivolumab 2tucatinib 1regorafenib 1pertuzumab 1niraparib 1milademetan 1dostarlimab 1cobimetinib 1brigimadlin 1atezolizumab 1alectinib 1Vemurafenib 1Tomography, X-Ray Computed 1Ramucirumab 1Radiation 1Positron-Emission Tomography 1Paclitaxel 1Magnetic Resonance Imaging 1HhAntag691 1Fulvestrant 1Erlotinib Hydrochloride 1Clinical Trials, Phase II as Topic 1Carboplatin 1Brachytherapy 1Antibodies 1AZD9833 1AZD5305 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Biliary Tract Neoplasms × atezolizumab × Genitourinary × Clear all
NCT02091141 2024-07-23

My Pathway: A Study Evaluating Herceptin/Perjeta, Tarceva, Zelboraf/Cotellic, Erivedge, Alecensa, and Tecentriq Treatment Targeted Against Certain Molecular Alterations in Participants With Advanced Solid Tumors

Genentech, Inc.

Phase 2 Completed
673 enrolled 22 charts
GastrointestinalGenitourinary

Biliary Tract Neoplasms, Urinary Bladder Neoplasms, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡